JP2015522270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522270A5 JP2015522270A5 JP2015519248A JP2015519248A JP2015522270A5 JP 2015522270 A5 JP2015522270 A5 JP 2015522270A5 JP 2015519248 A JP2015519248 A JP 2015519248A JP 2015519248 A JP2015519248 A JP 2015519248A JP 2015522270 A5 JP2015522270 A5 JP 2015522270A5
- Authority
- JP
- Japan
- Prior art keywords
- ospa
- seq
- positions
- disulfide bond
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 52
- 229920001184 polypeptide Polymers 0.000 description 49
- 239000012634 fragment Substances 0.000 description 38
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 241000589968 Borrelia Species 0.000 description 21
- 208000016604 Lyme disease Diseases 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 235000018417 cysteine Nutrition 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 241000589969 Borreliella burgdorferi Species 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108700006640 OspA Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940099789 ospa protein Drugs 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 150000001945 cysteines Chemical class 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 230000029226 lipidation Effects 0.000 description 5
- 241000568336 Borreliella bavariensis Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004900 c-terminal fragment Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010061591 Borrelia infection Diseases 0.000 description 2
- 241000589977 Borrelia turicatae Species 0.000 description 2
- 241000142472 Borreliella andersonii Species 0.000 description 2
- 241001478201 Borreliella japonica Species 0.000 description 2
- 241000004488 Borreliella sinica Species 0.000 description 2
- 241000019016 Borreliella spielmanii Species 0.000 description 2
- 241000204955 Colorado tick fever virus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical group NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920002851 polycationic polymer Polymers 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000605281 Anaplasma phagocytophilum Species 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000124827 Borrelia duttonii Species 0.000 description 1
- 241000589978 Borrelia hermsii Species 0.000 description 1
- 241001536361 Borrelia lonestari Species 0.000 description 1
- 241000216520 Borrelia miyamotoi Species 0.000 description 1
- 241000589976 Borrelia parkeri Species 0.000 description 1
- 241001148604 Borreliella afzelii Species 0.000 description 1
- 241000908527 Borreliella bissettii Species 0.000 description 1
- 241001148605 Borreliella garinii Species 0.000 description 1
- 241001446608 Borreliella lusitaniae Species 0.000 description 1
- 241000565673 Borreliella tanukii Species 0.000 description 1
- 241000582024 Borreliella turdi Species 0.000 description 1
- 241000876423 Borreliella valaisiana Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241001335250 Heartland virus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 241000604969 Neorickettsia sennetsu Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000606720 Rickettsia australis Species 0.000 description 1
- 241000606699 Rickettsia conorii Species 0.000 description 1
- 241001495405 Rickettsia helvetica Species 0.000 description 1
- 241001495398 Rickettsia parkeri Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003239 encephalitis vaccine Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261668627P | 2012-07-06 | 2012-07-06 | |
| US61/668,627 | 2012-07-06 | ||
| US13/802,991 US8986704B2 (en) | 2012-07-06 | 2013-03-14 | Mutant fragments of OspA and methods and uses relating thereto |
| US13/802,991 | 2013-03-14 | ||
| PCT/EP2013/064403 WO2014006226A1 (en) | 2012-07-06 | 2013-07-08 | MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522270A JP2015522270A (ja) | 2015-08-06 |
| JP2015522270A5 true JP2015522270A5 (enExample) | 2015-09-17 |
| JP6276258B2 JP6276258B2 (ja) | 2018-02-07 |
Family
ID=49878705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519248A Active JP6276258B2 (ja) | 2012-07-06 | 2013-07-08 | ＯｓｐＡの変異型断片、並びにそれに関する方法および使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US8986704B2 (enExample) |
| EP (3) | EP2869839B1 (enExample) |
| JP (1) | JP6276258B2 (enExample) |
| KR (2) | KR102190981B1 (enExample) |
| CN (2) | CN104487084B (enExample) |
| AU (2) | AU2013285364B2 (enExample) |
| CA (1) | CA2876541C (enExample) |
| CY (1) | CY1120772T1 (enExample) |
| DK (1) | DK2869839T3 (enExample) |
| EA (2) | EA033007B1 (enExample) |
| ES (2) | ES2800873T3 (enExample) |
| HR (1) | HRP20181689T1 (enExample) |
| HU (1) | HUE041286T2 (enExample) |
| LT (1) | LT2869839T (enExample) |
| MX (2) | MX391136B (enExample) |
| NZ (2) | NZ733026A (enExample) |
| PL (1) | PL2869839T3 (enExample) |
| PT (1) | PT2869839T (enExample) |
| RS (1) | RS57847B1 (enExample) |
| SI (1) | SI2869839T1 (enExample) |
| SM (1) | SMT201800557T1 (enExample) |
| TR (1) | TR201815419T4 (enExample) |
| WO (1) | WO2014006226A1 (enExample) |
| ZA (1) | ZA201409222B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| MX369195B (es) * | 2014-01-09 | 2019-10-31 | Valneva Austria Gmbh | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
| WO2015199234A1 (ja) * | 2014-06-27 | 2015-12-30 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物の塩 |
| WO2016022958A2 (en) * | 2014-08-07 | 2016-02-11 | The Trustees Of Columbia University In The City Of New York | Tick-associated virus sequences and uses thereof |
| WO2017108902A1 (en) * | 2015-12-23 | 2017-06-29 | Novartis Ag | Oil-in-water emulsions including retinoic acid |
| US11345969B2 (en) | 2016-02-11 | 2022-05-31 | The Translational Genomics Research Institute | Systems and methods for the detection of infectious diseases |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| KR20190001421U (ko) | 2019-05-26 | 2019-06-13 | 이준형 | 노크형 내부 수납식 칫솔 |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| CN111269919B (zh) * | 2020-03-19 | 2021-07-13 | 四川农业大学 | 玉米基因ZmLIP2及其应用 |
| IL297166A (en) * | 2020-04-09 | 2022-12-01 | Valneva Austria Gmbh | Compositions comprising three ospa fusion proteins for medical use |
| US20240026412A1 (en) * | 2020-04-09 | 2024-01-25 | Valneva Austria Gmbh | Improved methods of producing a lipidated protein |
| WO2023034932A1 (en) * | 2021-09-02 | 2023-03-09 | Vaxcyte, Inc. | Stabilization of adjuvanted vaccine compositions and their use |
| EP4743110A1 (en) | 2023-07-10 | 2026-05-20 | Dynavax Technologies Corporation | Lyme disease vaccines containing an adjuvant and Borrelia outer surface protein A and C antigens |
| JP2026525284A (ja) | 2023-07-10 | 2026-07-29 | ダイナヴァックス テクノロジーズ コーポレイション | アジュバントおよびｂｏｒｒｅｌｉａ細胞表層タンパク質ａ抗原を含むライム病ワクチン |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) * | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| EP1311540B1 (en) * | 2000-08-18 | 2007-12-19 | Research Foundation Of State University Of New York | Altered ospa of borrelia burgdorferi |
| UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| EP2289906A1 (en) | 2006-09-15 | 2011-03-02 | Intercell AG | Borrelia antigens |
| EP2468300B1 (en) * | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US8466259B2 (en) | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
| TWI376385B (en) | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
| EP2470664A4 (en) | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
| US8623375B2 (en) | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| US9925257B2 (en) | 2011-09-23 | 2018-03-27 | Forsyth Dental Infirmary For Children | Vaccine and therapeutic delivery system |
| CN103974834B (zh) | 2011-12-06 | 2017-09-05 | 慕贝尔碳纤维技术有限公司 | 由纤维增强材料制造的车轮及制造相应车轮的方法 |
| EP4400115A3 (en) | 2011-12-06 | 2024-10-23 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| MX369195B (es) | 2014-01-09 | 2019-10-31 | Valneva Austria Gmbh | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| JP6947727B2 (ja) | 2015-12-10 | 2021-10-13 | ナショナル リサーチ カウンシル オブ カナダ | 脂質化肺炎球菌抗原組成物、調製方法及び使用 |
| WO2018189372A1 (en) | 2017-04-13 | 2018-10-18 | Valneva Austria Gmbh | Multivalent ospa polypeptides and methods and uses relating thereto |
| WO2019092002A1 (en) | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| US20240026412A1 (en) | 2020-04-09 | 2024-01-25 | Valneva Austria Gmbh | Improved methods of producing a lipidated protein |
| IL297166A (en) | 2020-04-09 | 2022-12-01 | Valneva Austria Gmbh | Compositions comprising three ospa fusion proteins for medical use |
-
2013
- 2013-03-14 US US13/802,991 patent/US8986704B2/en active Active
- 2013-07-08 EA EA201590162A patent/EA033007B1/ru unknown
- 2013-07-08 CN CN201380035702.7A patent/CN104487084B/zh active Active
- 2013-07-08 HU HUE13734430A patent/HUE041286T2/hu unknown
- 2013-07-08 LT LTEP13734430.5T patent/LT2869839T/lt unknown
- 2013-07-08 EP EP13734430.5A patent/EP2869839B1/en active Active
- 2013-07-08 JP JP2015519248A patent/JP6276258B2/ja active Active
- 2013-07-08 KR KR1020157001969A patent/KR102190981B1/ko active Active
- 2013-07-08 NZ NZ73302613A patent/NZ733026A/en unknown
- 2013-07-08 PT PT13734430T patent/PT2869839T/pt unknown
- 2013-07-08 RS RS20181244A patent/RS57847B1/sr unknown
- 2013-07-08 NZ NZ703597A patent/NZ703597A/en unknown
- 2013-07-08 CA CA2876541A patent/CA2876541C/en active Active
- 2013-07-08 CN CN201710809730.XA patent/CN107602676B/zh active Active
- 2013-07-08 MX MX2018014949A patent/MX391136B/es unknown
- 2013-07-08 ES ES18163951T patent/ES2800873T3/es active Active
- 2013-07-08 SM SM20180557T patent/SMT201800557T1/it unknown
- 2013-07-08 WO PCT/EP2013/064403 patent/WO2014006226A1/en not_active Ceased
- 2013-07-08 PL PL13734430T patent/PL2869839T3/pl unknown
- 2013-07-08 SI SI201331205T patent/SI2869839T1/sl unknown
- 2013-07-08 MX MX2015000013A patent/MX364623B/es active IP Right Grant
- 2013-07-08 ES ES13734430.5T patent/ES2688883T3/es active Active
- 2013-07-08 EA EA201991059A patent/EA201991059A1/ru unknown
- 2013-07-08 DK DK13734430.5T patent/DK2869839T3/en active
- 2013-07-08 KR KR1020207035357A patent/KR102393038B1/ko active Active
- 2013-07-08 EP EP18163951.9A patent/EP3360568B1/en active Active
- 2013-07-08 TR TR2018/15419T patent/TR201815419T4/tr unknown
- 2013-07-08 EP EP20158277.2A patent/EP3689372B1/en active Active
- 2013-07-08 HR HRP20181689TT patent/HRP20181689T1/hr unknown
- 2013-07-08 US US14/412,722 patent/US20150232517A1/en not_active Abandoned
- 2013-07-08 AU AU2013285364A patent/AU2013285364B2/en active Active
-
2014
- 2014-12-15 ZA ZA2014/09222A patent/ZA201409222B/en unknown
-
2015
- 2015-02-17 US US14/623,681 patent/US20150250865A1/en not_active Abandoned
-
2016
- 2016-09-16 US US15/267,372 patent/US9926343B2/en active Active
- 2016-09-22 US US15/272,581 patent/US10544194B2/en active Active
-
2017
- 2017-08-22 AU AU2017218974A patent/AU2017218974C1/en active Active
-
2018
- 2018-02-27 US US15/906,618 patent/US11208439B2/en active Active
- 2018-10-18 CY CY181101073T patent/CY1120772T1/el unknown
-
2019
- 2019-12-04 US US16/702,885 patent/US11466058B2/en active Active
-
2021
- 2021-11-02 US US17/517,477 patent/US12195501B2/en active Active
-
2022
- 2022-09-14 US US17/932,226 patent/US20230295245A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260070950A1 (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| US20230295245A1 (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| JP2013529078A5 (enExample) | ||
| JP2013529077A5 (enExample) | ||
| RU2012153752A (ru) | Химерные гены ospa, белки и способы их применения | |
| JP2026081263A (ja) | 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 | |
| CN102180971B (zh) | 重组β淀粉样肽B细胞表位多肽嵌合抗原、其制备方法和应用 | |
| EP3029073B1 (en) | Polyvalent chimeric ospc vaccinogen and diagnostic antigen | |
| US20250281589A1 (en) | Compositions and methods for eliciting an immune response protective against lyme disease | |
| SE0901565A1 (sv) | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi | |
| TW202306966A (zh) | 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物 | |
| HK40016829A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| CN107849119A (zh) | 用于治疗和预防IgE介导的疾病的疫苗 | |
| HK40016829B (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| HK1229827B (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| HK1229827A1 (en) | Mutant fragments of ospa and methods and uses relating thereto |